COMPANION DIAGNOSTIC MARKETS

"COMPANION DIAGNOSTIC MARKETS, THE FUTURE OF DIAGNOSTICS BY APPLICATION, TECHNOLOGY AND FUNDING.  WITH EXECUTIVE AND CONSULTANT GUIDES 2023-2027"

“Companion Diagnostics are changing cancer management and are poised to move into new therapeutic eras. Dawn of a new age in medical treatment….”

 541 pages packed with information.

Companion Diagnostics are poised to revolutionize the diagnostics industry.  The market is finally moving out of the lab and into the clinic.  Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future.   Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

 Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities.  And some players are already taking the lead.  It is a dynamic market situation with enormous opportunity.  Diagnostic companies are trying to back the right horse.  The science is racing forward.  And the cost of molecular diagnostics continues to fall.

 Companion Diagnostic Markets" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand New Nucleic Acid Testing pricing in detail.   Forecast demand for new testing regimes or technologies.  Make research investment decisions.  Specific growth and market size estimates for your area of interest is normally provided without additional charges.  Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.  Again, assistance in using the information is normally provided without additional charges. 

 Take a look at the Table of Contents.

The report includes detailed breakouts for 18 Countries and 4 Regions.  A detailed breakout for any country or specific area in the world is available to purchasers of the report.

Send an email to us at service@howesoundresearch.com and we will happily email you a FREE copy of SAMPLE PAGES FROM THIS REPORT without any obligation on your part.  

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. 

He is an experienced business and clinical professional.  He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping."  He has worked in laboratory testing and management for over 20 years.  Mr. Powell’s education includes:

B.Sc. (Chemistry) University of BC

M.B.A. (Finance and Policy) University of BC

Market Research  - Burke Institute

Finance for Senior Executives - Harvard Business School